Release date: 2008-06-30 STMicroelectronics and Debiotech have unveiled the first prototype of a groundbreaking disposable insulin nanopump, marking a major step forward in diabetes care. This innovative microdevice is designed to be mounted on a nearly invisible applicator, enabling continuous and precise insulin delivery for patients. The development represents a significant leap in medical technology, offering improved treatment efficiency and enhanced quality of life for individuals living with diabetes. The new nanopump leverages advanced microfluidic MEMS (Micro-Electro-Mechanical Systems) technology, allowing for highly accurate control over insulin dosing. It mimics the natural secretion process of insulin from pancreatic islets more closely than traditional methods, while also incorporating safety features that can detect potential malfunctions. This level of precision and reliability makes it a game-changer in the field of diabetes management. One of the most notable advantages of this device is its compact size—just one-fourth the size of conventional insulin pumps—making it more convenient and less intrusive for users. Additionally, because it is manufactured using large-scale semiconductor techniques, it can be produced at a low cost as a disposable product. This eliminates the high upfront costs typically associated with existing syringe pump systems, making it more accessible for both patients and healthcare providers. Continuous Subcutaneous Insulin Infusion (CSII), also known as insulin pump therapy, has gained popularity due to its ability to replace multiple daily injections with a single, programmable system. With the new nanopump, patients can easily adjust their insulin dosage throughout the day based on their individual needs. Developed by Debiotech and industrialized by STMicroelectronics, this device marks the first application of microfluidic MEMS technology in diabetes treatment. Benedetto Vigna, Vice President of STMicroelectronics’ MEMS division, expressed excitement about the progress, stating, “The successful initial trial of this revolutionary insulin nanopump brings us closer to commercialization.†He emphasized the importance of the partnership with Debiotech, highlighting how this small silicon-based device could significantly impact millions of lives globally. Dr. Frédéric Neftel, CEO of Debiotech, described the achievement as a milestone in the industrialization of insulin nanopumps. “This new infusion system combines exceptional reliability, performance, and patient safety,†he said. “Our collaboration with ST has been highly successful, both in terms of timing and results. Now, we are focused on establishing long-term partnerships with leading medical device companies to bring this innovation to market.†As the demand for more efficient and user-friendly diabetes treatments continues to grow, this breakthrough in microfluidic technology offers a promising future for patients around the world. With further development and commercialization, the disposable insulin nanopump could become a standard in diabetes care, improving outcomes and transforming the way insulin is delivered. DC 3V With Lithium Battery Smoke Alarm Dc 3V With Lithium Metal Battery Smoke Alarm,Lithium Metal Alarm,Lithium Metal Smoke Alarm,Lithium Metal Battery Smoke Alarm Guangdong Isafenest Co.,Ltd. , https://www.isfenest.com